Make an Inquiry
Accelerating Usher Syndrome Drug Development

Usher syndrome presents a complex therapeutic challenge, marked by progressive hearing loss and vision impairment with limited treatment options. Protheragen stands as a specialized partner in the development of novel therapeutics targeting Usher syndrome, offering a full spectrum of preclinical drug development services—from target validation through IND-enabling studies. Leveraging deep scientific expertise and advanced technology platforms, Protheragen delivers robust, data-driven solutions tailored to the unique requirements of Usher syndrome research. Our integrated approach ensures rigorous evaluation of candidate molecules, comprehensive pharmacology and toxicology assessments, and strict adherence to global regulatory standards. With a proven track record in rare disease drug development, Protheragen is committed to accelerating the advancement of innovative therapies for Usher syndrome, driving progress from discovery to clinical readiness and ultimately improving patient outcomes.

What is Usher SyndromeTargets for Usher SyndromeDrug Discovery and Development ServicesWhy Choose Us

What is Usher Syndrome

Usher syndrome is a genetically heterogeneous, autosomal recessive disorder characterized by the combination of sensorineural hearing loss and progressive vision loss due to retinitis pigmentosa, with or without vestibular dysfunction. It results from pathogenic variants in several genes essential for the development and maintenance of cochlear hair cells and retinal photoreceptors. Disruption of these protein complexes leads to degeneration of sensory cells in the inner ear and retina, causing the hallmark dual sensory impairment. Usher syndrome is the leading cause of combined deafness and blindness, affecting both sexes equally and occurring across all ethnic groups. Clinically, Usher syndrome is classified into three main types, varying in severity and age of onset of symptoms. Type 1 presents with profound congenital hearing loss, vestibular dysfunction, and early-onset vision loss; Type 2 features moderate to severe congenital hearing loss with normal balance and later-onset retinitis pigmentosa; Type 3 involves progressive post-lingual hearing loss, variable vision loss, and variable vestibular involvement. Diagnosis requires a multidisciplinary approach, including audiological and ophthalmological evaluations, vestibular testing, and genetic analysis. While there is no cure, management focuses on early intervention with hearing aids or cochlear implants, low-vision aids, educational support, and genetic counseling to optimize quality of life and functional independence.

Learn More

Targets for Usher Syndrome

Usher syndrome is driven by defects in a network of proteins crucial for the structure and function of sensory hair cells in the inner ear and photoreceptors in the retina. Key molecular targets include scaffold and adapter proteins such as harmonin (USH1C), sans (USH1G), and whirlin (WHRN), which form the core USH interactome, ensuring the assembly and stability of mechanotransduction complexes. Transmembrane adhesion proteins like protocadherin related 15 (PCDH15), usherin (USH2A), and clarin 1 (CLRN1) mediate cell-cell adhesion and are essential for hair bundle cohesion and synaptic signaling. Motor proteins such as myosin VIIA (MYO7A) facilitate the transport and localization of these complexes, while ion channel proteins like TMC1 enable the conversion of mechanical stimuli into electrical signals within hair cells. Mutations in these targets disrupt sensory cell integrity, leading to progressive hearing and vision loss characteristic of Usher syndrome. These molecular targets present promising avenues for therapeutic intervention. Gene therapy is at the forefront, with clinical trials underway for USH1C (harmonin) and MYO7A, and ongoing research for USH1G, USH2A, and CLRN1. Antisense oligonucleotide therapies and small molecule modulators are also being explored, particularly for larger or less accessible genes. The identification of these targets allows for the development of precision medicine approaches, including biomarker discovery for diagnosis and monitoring. Overall, the therapeutic landscape for Usher syndrome is rapidly evolving, with validated and emerging targets supporting preclinical and clinical strategies aimed at restoring sensory function and halting disease progression.

Learn More

Drug Discovery and Development Services

In Vitro Efficacy Testing ServicesIn Vivo Model DevelopmentPK/PD Study ServicesIn Vivo Toxicity Assessment ServicesBiomarker Analysis Services
In Vitro Efficacy Testing Services

Online Inquiry

Our In Vitro Efficacy Testing Service accelerates Usher syndrome drug discovery by evaluating candidate compounds targeting key proteins such as Clarin 1. Utilizing HEK293 cells expressing mutant Clarin 1, we employ quantitative DAPI dye-based assays at 2 and 24 hours post-treatment to assess cell viability and nuclear integrity. The service determines EC-50 values, enabling precise measurement of compound potency and therapeutic potential. By capturing both acute and longer-term cellular responses, our platform provides robust, sensitive, and actionable data to inform early-stage drug development and support effective prioritization of therapeutic candidates for Usher syndrome.

Clarin 1

Learn More

Why Choose Us

Choosing Protheragen for your Usher syndrome drug development needs means partnering with a team deeply committed to advancing therapeutics in this challenging field. Protheragen’s specialized expertise in Usher syndrome research is supported by years of focused experience and a thorough understanding of the disease’s unique complexities. Our professional teams consist of dedicated scientists and industry veterans who utilize state-of-the-art technology platforms to accelerate preclinical drug development. Protheragen has established a strong track record of delivering reliable, high-quality preclinical services, consistently meeting the rigorous expectations of our partners. We adhere to the highest quality standards and maintain strict regulatory compliance, ensuring that every stage of development is conducted with integrity and precision. Above all, Protheragen is driven by a commitment to making a meaningful impact in the lives of those affected by Usher syndrome. We are devoted to translating scientific innovation into tangible therapeutic solutions, and we take pride in being a trusted partner for organizations seeking to bring new hope to patients and families worldwide.

FAQs for Our Services

Q: What are the main preclinical research challenges specific to developing drugs for Usher syndrome?

A: Usher syndrome presents unique preclinical research challenges, including the rarity and genetic heterogeneity of the disease, which complicate the development of representative animal models. Additionally, the dual sensory impairment (hearing and vision loss) requires comprehensive efficacy assessments across multiple organ systems. Our company addresses these challenges by utilizing state-of-the-art genetic engineering to create robust animal and cellular models, and by integrating multi-modal endpoints to thoroughly evaluate candidate therapeutics.

Q: What regulatory considerations are important for preclinical drug development in Usher syndrome?

A: Given the orphan status of Usher syndrome, regulatory agencies such as the FDA and EMA offer specific guidance and incentives, but also require rigorous demonstration of safety and proof-of-concept efficacy in relevant preclinical models. Our team is experienced in preparing comprehensive IND-enabling packages, including pharmacology, toxicology, and biodistribution studies, and we maintain close communication with regulatory authorities to ensure alignment with the latest requirements and opportunities for accelerated pathways.

Q: What technical aspects should be considered when designing preclinical studies for Usher syndrome therapies?

A: Technical considerations include selecting appropriate animal models that faithfully recapitulate both the auditory and visual aspects of Usher syndrome, developing sensitive assays to measure functional outcomes, and optimizing drug delivery methods (e.g., intravitreal, cochlear, or systemic administration). Our company leverages advanced imaging, electrophysiological, and behavioral testing platforms, and customizes study designs to maximize translational relevance and data quality.

Q: What are the typical timeline and cost considerations for preclinical drug development in Usher syndrome?

A: The preclinical phase for Usher syndrome drug development typically spans 18-36 months, depending on the complexity of the therapeutic modality and required studies. Costs can range from $2 to $8 million, influenced by the need for specialized animal models, advanced efficacy endpoints, and comprehensive safety assessments. We provide detailed project planning, milestone-based budgeting, and flexible resourcing to help clients optimize timelines and manage costs efficiently.

Q: What are the key success factors in preclinical drug development for Usher syndrome?

A: Success in preclinical development for Usher syndrome hinges on selecting the right models, demonstrating robust target engagement and efficacy, ensuring safety across relevant organ systems, and generating high-quality, reproducible data for regulatory submissions. Early and strategic engagement with regulatory bodies, as well as collaboration with academic and patient advocacy groups, further increases the likelihood of successful translation to clinical trials. Our company excels in these areas, providing integrated services and expert guidance throughout the preclinical process.

Make an Inquiry
Important Links
Get in Touch with Us

Copyright © 2026 Protheragen. All rights reserved.